Gujarat Terce Laboratories Ltd (GUJTERC) is currently trading at 41.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Gujarat Terce Laboratories Limited is a mid‑sized Indian branded generics pharmaceutical company that manufactures and markets formulations across acute and chronic therapeutic areas from a WHO‑GMP compliant, automated facility at Chhatral; the plant has installed capacity of 270 million tablets and 108 million capsules per annum and sells through a field force spanning 13 states. Q3 FY26 showed a modest revenue decline of 3% year‑on‑year to INR 1,229.35 lacs while EBITDA rose 8% in the quarter and 6.8% for 9M FY26, driving EBITDA margin expansion to 10.16% in Q3 and 9.03% for 9M, reflecting operational efficiency gains despite top‑line rationalisation of low‑margin businesses. Reported PAT declined materially (27% in Q3 and 12.9% for 9M), and cash profit contracted, indicating near‑term earnings pressure possibly from non‑operating items, working capital timing or investments behind brand building, even as core operating profitability improved, signalling a trade‑off between quality of earnings and short‑term reported profit. The company highlights a brand‑led strategy supported by strong field execution and distribution: 8 leading brands, 134 products, about 150 medical representatives, relationships with over 32,700 practitioners, 30,074 chemists and 385 stockists across 224 districts, enabling deeper penetration in northern, western and central India and faster secondary sales conversion.

Over the past 52 weeks, Gujarat Terce Laboratories Ltd has traded between a low of ₹37.20 and a high of ₹73.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Gujarat Terce Laboratories Ltd has a market capitalization of approximately 30.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Gujarat Terce Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -26.70 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 30.02 Cr, Gujarat Terce Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Gujarat Terce Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Gujarat Terce Laboratories Ltd is -26.70. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.